SavedAdd your journal

Journals / Turkish Journal of Hematology / 2007 / Cilt: 24 - Sayı: 2

Lupus anticoagulant and anticardiolipin antibodies in SLE with secondary antiphospholipid antibody syndrome

Shveta GARG
Annamma KURIEN
Pages
69–74
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We concluded that the prevalence of lupus anticoagulant and anticardiolipin antibodies in SLE patients with secondary APLAS was 12% and 17%, respectively.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Thirty patients with systemic lupus erythematosus (SLE) and suspected secondary antiphospholipid antibody syndrome (APLAS) were evaluated in the study based on their clinical manifestations.
📊
Key Findings & Data:Twelve percent of patients had positive lupus anticoagulant and 78% had elevated anticardiolipin antibody titers.
💡
Conclusion & Impact:We concluded that the prevalence of lupus anticoagulant and anticardiolipin antibodies in SLE patients with secondary APLAS was 12% and 17%, respectively.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Lupus pıhtılaşma inhibitörü · Otoimmün hastalıklar · Protrombin zamanı

Özet

Thirty patients with systemic lupus erythematosus (SLE) and suspected secondary antiphospholipid antibody syndrome (APLAS) were evaluated in the study based on their clinical manifestations. The aim was to study the prevalence of various antiphospholipid antibodies, compare the tests used for their detection and to find a correlation between clinical and laboratory parameters. Coagulation tests used were activated partial thromboplastin time, dilute Russell viper venom time and kaolin clotting time and the results were analyzed statistically. In our study, arteriovenous thrombosis was more common than recurrent abortions and other clinical manifestations. Twelve percent of patients had positive lupus anticoagulant and 78% had elevated anticardiolipin antibody titers. We concluded that the prevalence of lupus anticoagulant and anticardiolipin antibodies in SLE patients with secondary APLAS was 12% and 17%, respectively. We also proved that dilute Russell viper venom time and kaolin clotting time proved to be much more specific tests and the anticardiolipin antibody a much more sensitive test.

🔖

Cite This Article

GARG, S., KURIEN, A. (2007). Lupus anticoagulant and anticardiolipin antibodies in SLE with secondary antiphospholipid antibody syndrome. Turkish Journal of Hematology, Cilt: 24 - Sayı: 2, 69–74. https://ajindex.com/articles/413224

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch W, Rauch J. International consensus statement as preliminary classification criteria for definite antiphospholipid syndrome. Report of an international workshop. Arthritis Rheumatol 1999;42:1309-11
  2. Brandt JT, Tripett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulant: an update. On behalf of the Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH. Thromb Hemostasis 1995;74:1185-90
  3. Hahn BH. Systemic lupus erythematosus. In: Kasper, ed. Harrison’s Principles of Internal Medicine. 16th ed. New York: Mc Graw-Hill Medical Publishing Division, 2005:1960-67
  4. Saxena R, Savaya AK, Dhot PS, Singh Y, Malaviya AN. Lupus anticoagulant and anticardiolipin antibodies in systemic lupus erythematosus. Natl Med J India 1994;7:163-5
  5. Malaviya AN, Singh RR, Singh YN, Kapoor SK, Kumar A. Prevalence of systemic lupus erythematosus in India. Lupus 1993;2:115-8
  6. Petri M, Rheinschmidt M, Whiting-O’Keefe Q, Hellmann D, Corash L. The frequency of lupus anticoagulant in systemic lupus erythematosus. Ann Intern Med 1987;106:524-31
  7. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa MC, Hughes GR, Ingelmo M; Euro-Phospholipid Project Group. Clinical and immunological manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-27
  8. Derksen RH. Lupus anticoagulant. Revival of our old phenomenon. Clin Exp Rheumatology 1985;3:349-57
  9. Levine JS, Branch W, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-63
  10. Cuadrado MJ, Mujie F, Munoz E, Khamashta MA, Hughes GR. Thrombocytopenia in antiphospholipid antibody syndrome. Ann Rheum Dis 1997;56:194-6
  11. Fong KY, Loizou S, Boey ML, Walport MJ. Anticardiolipin antibodies, hemolytic anaemia and thrombocytopenia in systemic lupus erythematosus. Br J Rheumatol 1992;31:453-5
  12. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in SLE and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990;112:682-98
  13. Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anticardiolipin a